Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

"We have already seen significant reduction of post-meal elevation of glucose in preclinical models with PAZ320," said David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics. "We are excited about our collaboration with Endocrinologist Sushela Chaidarun, M.D., Ph.D. and Dr. Laura E. Trask at Dartmouth Hitchcock Medical Center and the possibility to help millions of people with high blood sugar and diabetes."

PAZ320 is a chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. It is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal system to block the action of carbohydrate-hydrolyzing enzymes which break down carbohydrates into glucose and release it into the bloodstream. This clinical study will evaluate the safety and efficacy of PAZ320 when added to oral diabetes agents or insulin. The study population will consist of adults aged 18-75 years with Type 2 diabetes, either on oral agents or insulin with a BMI of 25-35 kg/m2 and with A1c of less than 9.0%.

"Given the many complications that stem from uncontrolled diabetes, it is important to implement measures that will better control glucose levels throughout the day," said Dr. Laura Trask, MD, Co-Principal Investigator of the study with Dr. Chaidarun. "By providing another way to appropriately control the postprandial glucose increase following a meal, diabetics may better control their glucose level."